Journey Strategic Wealth’s Vertex Pharmaceuticals VRTX Stock Holding History

Journey Strategic Wealth’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$957K	Buy	2,143 +702	+49%	+$327K	0.02%	191
2025 Q4	$653K	Buy	1,441 +487	+51%	+$210K	0.02%	249
2025 Q3	$374K	Sell	954 -649	-40%	-$271K	0.01%	384
2025 Q2	$714K	Buy	1,603 +809	+102%	+$373K	0.02%	217
2025 Q1	$385K	Buy	794 +72	+10%	+$33.6K	0.01%	281
2024 Q4	$291K	Sell	722 -61	-8%	-$28.3K	0.01%	338
2024 Q3	$364K	Buy	783 +255	+48%	+$122K	0.01%	283
2024 Q2	$247K	Buy	+528	New	+$229K	0.01%	301
2023 Q2	–	Sell	-716	Closed	-$226K	–	269
2023 Q1	$226K	Sell	716 -234	-25%	-$70.2K	0.02%	206
2022 Q4	$274K	Buy	950 +257	+37%	+$78.3K	0.03%	154
2022 Q3	$200K	Buy	+693	New	+$199K	0.03%	158

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Journey Strategic Wealth's VRTX Position: Q1 2026 in Review

Journey Strategic Wealth increased its Vertex Pharmaceuticals (VRTX) stake by 49% in Q1 2026, buying an estimated $327K and bringing the position to 2,143 shares worth $957K. The position accounts for 0.02% of the portfolio, ranked #191.

Journey Strategic Wealth first reported a position in VRTX in Q3 2022 and has held it in 11 quarters since. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Journey Strategic Wealth held 2,143 shares of Vertex Pharmaceuticals worth $957K as of Q1 2026.
Journey Strategic Wealth bought 702 Vertex Pharmaceuticals shares in Q1 2026, an estimated $327K.
Vertex Pharmaceuticals made up 0.02% of Journey Strategic Wealth's portfolio in Q1 2026, its #191 holding.
Journey Strategic Wealth first reported a position in Vertex Pharmaceuticals in Q3 2022 and has held it in 11 quarters since.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Journey Strategic Wealth's 13F filing for Q1 2026, filed 15 Apr 2026.